On July 10th, Gelunhui reported that Zhejiang Hisun Pharmaceutical (600267.SH) announced that its wholly-owned subsidiary, Hisun Pharmaceutical (Hangzhou) Co., Ltd. (referred to as "Hisun Hangzhou Company"), received the Chemical Drug Substance Marketing Authorization Approval Letter for Everolimus.
Everolimus is used for the treatment of adult patients with advanced renal cell carcinoma who have previously received treatment with sunitinib or sorafenib and failed; adult patients with unresectable, locally advanced or metastatic, well-differentiated (intermediate or high grade) progressive pancreatic neuroendocrine tumors; adult patients with locally advanced or metastatic and well-differentiated, progressive non-functioning gastrointestinal or lung neuroendocrine tumors (NETs) who are not suitable for surgical resection; adult and pediatric patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but who are not candidates for curative surgical resection, and adult patients with renal angiomyolipoma (TSC-AML) associated with TSC who do not require immediate surgery. In clinical use, everolimus can also be used to prevent rejection reactions after kidney and heart transplantation surgery.